Skip to content
Anksilon header banner v4.jpeg

Anksilon™ (buspirone hydrochloride)

Anksilon® (buspirone hydrochloride) is indicated for the short-term treatment of anxiety. It is a non-sedating anxiolytic with no known potential for dependence or withdrawal reactions. This information is intended for healthcare professionals to support prescribing decisions and patient counselling.
Shown no potential
for drug addiction
and dependence¹
No significant effect
on cognition and
functional impairment¹
No reported
withdrawal
reactions¹

¹As reported in the Anksilon Product Information.

 

When standard therapies are not an option, consider Anksilon® for the short‑term management of anxiety.

“

When standard therapies are not an option, consider Anksilon® for the short-term management of anxiety.

 

Anksilon® treatment consideration

When standard therapies are not an option, consider Anksilon® for the short-term management of anxiety.

Key features

  • • Non-sedating anxiolytic
  • • Shown to have low potential for dependence¹
  • • No significant psychomotor impairment¹
  • • Favourable tolerability profile suitable for longer-term use when clinically appropriate¹
  • • Does not potentiate CNS depression with alcohol¹

¹As reported in the Anksilon Product Information.

Key Product Information

PBS Note

This product is not listed on the Pharmaceutical Benefits Scheme (PBS). Anksilon® is available on private prescription only.

Product Presentations

Strength Description Markings
5 mg White, oval tablet Debossed ‘ORN 30’
10 mg White, oval tablet Debossed ‘ORN 31’

Resources

View All Resources

Find additional clinical materials and patient-support tools in the full Anksilon resource library.

Order Materials

Request printed Anksilon resources and demonstration packs for use in your practice.